(3β,5β)-3-[(6-Deoxy-3-O-methyl-α-L-glucopyranosyl)oxy]-14-hydroxy-19-oxocard-20(22)-enolid
Bezeichnung:(3β,5β)-3-[(6-Deoxy-3-O-methyl-α-L-glucopyranosyl)oxy]-14-hydroxy-19-oxocard-20(22)-enolid
CAS-Nr1182-87-2
Englisch Name:PERUVOSIDE
CBNumberCB0266619
SummenformelC30H44O9
Molgewicht548.66
MOL-Datei1182-87-2.mol
Synonyma
(3β,5β)-3-[(6-Deoxy-3-O-methyl-α-L-glucopyranosyl)oxy]-14-hydroxy-19-oxocard-20(22)-enolid
(3β,5β)-3-[(6-Deoxy-3-O-methyl-α-L-glucopyranosyl)oxy]-14-hydroxy-19-oxocard-20(22)-enolid physikalisch-chemischer Eigenschaften
Schmelzpunkt | 161-164°C |
alpha | D22 -71.7° (c = 1.54 in methanol) |
Siedepunkt | 540.83°C (rough estimate) |
Dichte | 1.1277 (rough estimate) |
Brechungsindex | 1.5500 (estimate) |
storage temp. | 2-8°C |
Löslichkeit | Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly) |
pka | 12.92±0.70(Predicted) |
Aggregatzustand | powder |
Farbe | light yellow |
Kennzeichnung gefährlicher | T |
R-Sätze: | 23/24/25 |
S-Sätze: | 36/37/39-45 |
WGK Germany | 3 |
RTECS-Nr. | FH4915000 |
Toxizität | cat,LD50,intravenous,145ug/kg (0.145mg/kg),GASTROINTESTINAL: NAUSEA OR VOMITINGCARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION)CARDIAC: CHANGE IN RATE,Archives Internationales de Pharmacodynamie et de Therapie. Vol. 126, Pg. 412, 1960. |